drugset / Trial / NCT04974827
A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
In this single-arm study, patient with cervical cancer who had recurrence of the pelvic wall after surgery ± Abdominal aortic lymph node metastasis will be included to evaluate the efficacy and safety of camrelizumab combined with concurrent chemoradiation and subsequent maintenance therapy
Timeline
- Start
- 2021-05-20
- Primary completion
- 2023-05-20
- Completion
- 2023-05-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Carboplatin | Small molecule | 2 unknown | Intravenous |
| Subject | Cisplatin | Other / unclassified | 40 mg/m2 | Intravenous |